🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🌟 Big moment for Halia Therapeutics! 🌟 Our CEO, Dave Bearss, represented us at the #PrixGalienUSA Awards, where we were honored as a finalist for Best Startup! 🏆 Huge thanks to our team for their dedication to healthcare innovation! 💪💙 #Biotech #Innovation #HaliaTherapeutics

Our CEO, Dr. Dave Bearss, shares how targeting the NLRP3 inflammasome could transform treatments for Alzheimer’s, obesity, and more. Dive into the latest insights here. #NLRP3 #HaliaTx #Citeline #Inflammation

🎯 At Halia, we invest in people & community. Ben, Devan, & Taylor—once lab techs, now leaders in lab management, biomarkers, & biz dev—manned our booth at BYU's BioHive Career Fair. We're growing talent & biotech innovation to drive our mission forward! 🚀 #CareerGrowth

🔬 Excited to announce: Our CEO Dave Bearss will present groundbreaking oral obesity therapeutics at #ObesityInnovation Summit in San Diego! 📅 Dec 11 @ 5pm PT - "Exploring Oral Obesity Therapeutics" Plus: Catch his insights on supply chain challenges (2:40pm PT) More info:

Exciting News from Halia Therapeutics! 📢 Positive topline results from our Phase 2 trial of HT-6184 for lower-risk myelodysplastic syndromes (LR-MDS)! ✅ Breakthrough Results: Our oral NEK7/NLRP3 inflammasome inhibitor showed significant hematological improvements in patients.

Great week at #ASH2024! Halia's CEO & COO, the Bearss brothers, connected with MDS experts, sparking exciting conversations. Following yesterday's PR, we're more energized than ever to advance patient care through innovation. 💡🩺 #Hematology #Innovation #HaliaTherapeutics

Halia CEO Dr. Dave Bearss shared how HT-6184 reduces adipose inflammation, which may translate to mitigating GLP-1 side effects, and supports sustained weight loss. We’re advancing obesity care! Learn more: haliatx.com #ObesityCare #Innovation #Biotech #HaliaTx

.Dave Bearss, CEO of Halia Therapeutics, discusses Halia’s primary goals for the first half of 2025 and an ongoing commitment to developing transformative therapies targeting chronic inflammatory diseases. To learn more, please visit: haliatx.com

Halia Therapeutics advances to the second stage of its Phase 2 trial for HT-6184, a first-in-class, oral NEK7/NLRP3 inflammasome inhibitor in lower-risk MDS patients. Promising topline results show exciting potential. #UtahLifeSciences 🔗 Learn more: ow.ly/TQHl50UsUE8

Halia Therapeutics is partnering with M42 Health (M42’s) IROS to launch a clinical study in the UAE focused on obesity treatment with our innovative therapeutic, HT-6184. Learn more about our collaboration: zawya.com/en/press-relea…

Let the JPM 2025 festivities begin! Dave Bearss presented at the BioPharma Obesity Innovation Forum. Targeting Inflammation in Obesity with HT-6184 enhances weight loss & glucose control of GLP-1 agonists in pre-clinical models. #HaliaTx #Obesity #NLRP3

Excited to kick off JPM week by stepping up to the Nasdaq podium! Halia Therapeutics Dave Bearss is ringing in the future of biotech innovation. #JPM25 #Biotech #Innovation”

Every Innovation story matters. We look forward to Dave Bearss sharing our perspective on chronic inflammatory diseases at the WuXi Global Forum 2025 wxpress.wuxiapptec.com/detail/927/wux…

Halia Therapeutics is proud to sponsor the BioHive event, BioHive Live. Join us on Feb 20, 2025, as our CEO, Dave Bearss , speaks on the "Why We Do It" panel (1:05-1:35 PM) about biotech innovation & inflammation-targeted therapies. Let’s connect & push the future of

APOE4 carriers have up to a 60% risk of developing Alzheimer's. Can we change that? At Halia Therapeutics, we're developing HT-4253, a novel therapeutic that targets LRRK2 to modulate RAB10, mimicking a naturally protective mutation. 📢 Join us at #AAIC in Miami (March 17-18)

Exercise fights inflammation, but HT-6184 takes it further. 🏃‍♂️ Regular workouts shrink fat cells & reduce their inflammatory impact, improving metabolic health. But what if we could enhance this process? 🔬 HT-6184 targets adipose tissue inflammation, shifting fat cells from

IL-1β+ macrophages and the control of pathogenic inflammation in cancer: Trends in Immunology cell.com/trends/immunol…

Halia Therapeutics has completed enrollment in its Phase 2a trial of HT-6184 for lower-risk MDS. HT-6184 targets NEK7–NLRP3 to disrupt clonal inflammation and improve hematologic outcomes. Topline results expected later this year. 🔗 haliatx.com/halia-therapeu… #MDS #Biotech

“Halia is working to crack inflammatory disorders.” Thanks to Dr. Mike Kennedy for spotlighting us during the Science, Space & Tech Committee hearing, and to BioUtah for your advocacy! #HaliaTx #UtahBiotech #SciencePolicy #GeneticResilience

David Bearss, PhD, CEO of Halia Therapeutics, delivered the keynote at #MedInvestmentForum2025 in Abu Dhabi on May 29, presenting: “Pioneering a New Era of Medicine by Unlocking the Body’s Power of Genetic Resilience.” 🔗 Read more: ow.ly/5xEc50W5Kzh #BioUtah #LifeSciences